Analyst Ratings For MacroGenics Inc (NASDAQ:MGNX)
Today, HC Wainwright set its price target on MacroGenics Inc (NASDAQ:MGNX) to $34.00 per share.
There are 8 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on MacroGenics Inc (NASDAQ:MGNX) is Buy with a consensus target price of $33.00 per share, a potential 110.59% upside.
Some recent analyst ratings include
- 9/10/2018-MacroGenics Inc (NASDAQ:MGNX) has coverage initiated with a Buy ➝ Buy rating and $30.00 price target
- 8/8/2018-MacroGenics Inc (NASDAQ:MGNX) had its Buy rating reiterated by Cowen
- 5/31/2018-MacroGenics Inc (NASDAQ:MGNX) has coverage initiated with a Outperform rating and $33.00 price target
- 5/8/2018-MacroGenics Inc (NASDAQ:MGNX) had its Outperform rating reiterated by Wedbush with a $44.00 price target
- 4/6/2018-MacroGenics Inc (NASDAQ:MGNX) had its Outperform rating reiterated by Leerink Swann
- 3/14/2018-MacroGenics Inc (NASDAQ:MGNX) had its Equal Weight ➝ Equal Weight rating reiterated by Morgan Stanley with a $26.00 price target
- On 3/12/2018 Eric Blasius Risser, SVP, sold 1,000 with an average share price of $31.08 per share and the total transaction amounting to $31,080.00.
- On 3/5/2018 James Karrels, CFO, sold 5,000 with an average share price of $31.00 per share and the total transaction amounting to $155,000.00.
- On 3/2/2018 Eric Blasius Risser, SVP, sold 4,000 with an average share price of $30.00 per share and the total transaction amounting to $120,000.00.
- On 2/28/2018 Eric Blasius Risser, SVP, sold 1,000 with an average share price of $25.01 per share and the total transaction amounting to $25,010.00.
- On 2/28/2018 Lynn Cilinski, VP, sold 23,967 with an average share price of $25.01 per share and the total transaction amounting to $599,414.67.
- On 1/24/2018 Eric Blasius Risser, SVP, sold 3,000 with an average share price of $22.50 per share and the total transaction amounting to $67,500.00.
- On 1/17/2018 Jon Marc Wigginton, SVP, sold 5,000 with an average share price of $20.00 per share and the total transaction amounting to $100,000.00.
About MacroGenics Inc (NASDAQ:MGNX)
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, and autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also developing Flotetuzumab, a DART molecule that targets CD123 and CD3; MGA012, a monoclonal antibody, which targets programmed cell death protein 1 (PD-1); MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; MGD019, a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company develops MGD009, a DART molecule recognizes B7-H3 and CD3; MGC018, a B7-H3 antibody-drug conjugate; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells and CD3-expressing T cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. The company also has a translational research agreement with NanoString Technologies, Inc. for the identification and development of biomarkers for MGD013 program. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Recent Trading Activity for MacroGenics Inc (NASDAQ:MGNX)
Shares of MacroGenics Inc closed the previous trading session at 15,67 −1,35 7,93 % with 262400 shares trading hands.
